# US 2012/0258539 A1 · Use of nibp polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0258539 A1
- Document ID: US20120258539A1
- Status: Published application
- Kind: A1
- Application number: 13/499,932
- Filed: 2010-10-12
- Published: 2012-10-11
- Earliest claimed: 2009-10-13
- Assignees: Temple University of the Commonwealth of Higher Education Office of Technology Transfer
- Inventors: Wenhui Hu
- Web page: https://patentgrep.com/patent/US20120258539A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A61P 35/00: Antineoplastic agents
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for regulating NF-κB activation in cells comprising introducing into the cell a vector comprising a nucleic acid sequence encoding a NIK and IKK2 Binding Protein (NIBP) polypeptide, wherein the NIBP polypeptide is expressed in the cell, are provided. Also provided are methods for reversing the cancerous phenotype of a cancer cell and for modulating neuronal differentiation.

## Claims

### Claim 1

A method for inhibiting NF-κB activation in a cell, comprising introducing into the cell a vector comprising a nucleic acid sequence encoding a NIK and IKK2 Binding Protein (NIBP) polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 5-7, wherein the NIBP polypeptide is expressed in the cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell is a cancer cell.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cancer cell is selected from the group consisting of breast, gut, liver, colorectal, cervix, prostate, lung and brain cancer cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cell has constitutive NF-κB activation.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cell has induced NF-κB activation.

### Claim 6 (depends on 5)

The method of claim 5, wherein the NF-κB activation is induced by TNFα.

### Claim 7

A method for reversing the cancerous phenotype of a cancer cell, comprising introducing into the cell a vector comprising a nucleic acid sequence encoding a NIK and IKK2 Binding Protein (NIBP) polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-7 and 13-16, wherein the NIBP polypeptide is expressed in the cell.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cancer cell is selected from the group consisting of breast, gut, liver, colorectal, cervix, prostate, lung and brain cancer cells.

### Claim 9 (depends on 7)

The method of claim 7, wherein reversing the cancerous phenotype comprises inhibiting cell proliferation and inducing cell death.

### Claim 10

A method for modulating neuronal differentiation of a cell, comprising introducing into the cell a vector comprising a nucleic acid sequence encoding a NIK and IKK2 Binding Protein (NIBP) polypeptide, wherein the NIBP polypeptide is expressed in the cell, and the cell is selected from the group consisting of a neural stem cell (NSC), a neural progenitor cell (NPC), and a cell having disrupted NIBP expression.

### Claim 11

A host cell comprising a vector comprising a nucleic acid sequence encoding a NIK and IKK2 Binding Protein (NIBP) polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-7 and 13-16, wherein the cell is capable of expressing the NIBP polypeptide.
